Stay informed with the latest litigation news. Explore now

IP Verse

Synthon competitive analysis

Latest publications and patents of Synthon New

Explore the latest publications and patents granted to Synthon, showcasing their recent innovations and technological advancements.

Last updated on: Sep 8, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Synthon

EP3697392
Nov 15, 2023Tablets Comprising Tamsulosin And SolifenacinGranted And Under Opposition
EP3606511
Apr 20, 2022Pharmaceutical Composition Comprising Lenvatinib MesylateGranted And Under Opposition
EP3474865
Mar 2, 2022Process For Making SugammadexGranted And Under Opposition
EP2945948
Apr 29, 2020Crystalline Form Ii Of Anagrelide Hydrochloride MonohydrateOpposition Rejected
EP3206666
Dec 11, 2019Liquid Pharmaceutical Composition Comprising PemetrexedGranted And Under Opposition
EP2621889
Jul 17, 2019Process For Making Fingolimod Hydrochloride CrystalsRevoked
EP2658840
Jul 3, 2019Process For Making Fingolimod Hydrochloride CrystalsOpposition Rejected
EP2774606
Jan 30, 2019Pharmaceutical Composition Comprising Ivabradine Hydrochloride Polymorph IvRevoked
EP3008064
Nov 22, 2017Stable Pemetrexed Arginine Salt And Compositions Comprising ItRevoked

Latest oppositions filed by Synthon

Explore patent oppositions filed by Synthon against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 11, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3242666
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALSJul 15, 2025
EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 14, 2025
EP3801459
Methods Of Treating Conditions Related To The S1P1 ReceptorARENA PHARMACEUTICALSMay 7, 2025
EP3439662
Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-CarboxamideLOXO ONCOLOGYApr 11, 2025
EP3529360
Methods For Preventing Cardiovascular Events Through Proprotein Convertase Subtilisin Kexin 9 (Pcsk9) Protein ReductionNOVARTISJan 10, 2025
EP3270909
Fixed Dose Combinations Comprising Etc1002 And One Or More Statins For Treating Or Reducing Cardiovascular RiskESPERION THERAPEUTICSJul 30, 2024
EP3263106
Method For Suppressing Bitterness Of Quinoline DerivativeEISAI R&D MANAGEMENTJul 25, 2024
EP3626270
New UseNOVARTISJul 10, 2024
EP3294283
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISDec 7, 2023
EP3647783
Identifying Patient Response To S1P Receptor Modulator AdministrationNOVARTISSep 21, 2023

Latest patents of Synthon opposed by its competitors

Explore Synthon's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3697392
Nov 15, 2023Tablets Comprising Tamsulosin And Solifenacin3
EP3606511
Apr 20, 2022Pharmaceutical Composition Comprising Lenvatinib Mesylate1
EP3474865
Mar 2, 2022Process For Making Sugammadex2
EP2945948
Apr 29, 2020Crystalline Form Ii Of Anagrelide Hydrochloride Monohydrate1
EP3206666
Dec 11, 2019Liquid Pharmaceutical Composition Comprising Pemetrexed1
EP2621889
Jul 17, 2019Process For Making Fingolimod Hydrochloride Crystals1
EP2658840
Jul 3, 2019Process For Making Fingolimod Hydrochloride Crystals1
EP2774606
Jan 30, 2019Pharmaceutical Composition Comprising Ivabradine Hydrochloride Polymorph Iv5
EP3008064
Nov 22, 2017Stable Pemetrexed Arginine Salt And Compositions Comprising It1

Latest PTAB cases involving Synthon New

Discover the latest PTAB cases involving Synthon, highlighting their recent legal challenges and patent disputes.

Top competitors of Synthon

Top competitors of Synthon based on patent oppositions.